Search
CELL BANK Website

Back Back
RCB1546 : JHOS-3  update : 2018/08/01
CommentJapanese ovarian serous adenocarcinoma. Said CA125 producing. Cell growth is slow. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank
Fax. +81-29-836-9130
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 1999
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 48 years
Tissue ovary
Case history ovarian serous adenocarcinoma
Metastastatic ability Yes
Metastatsd tissue lymph node
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 15% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/10 days, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Isozyme LD, NP
Chromosome mode 42-86(50) : 42(27),43(8),79(2),80(2),81(3)/
Reference information Reference 0
User's Publication 2


To topTop
Reference

To topTop
User's Publication
11501  Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.  Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.  Biochem. Biophys. Res. Commun.  2019    PubMed ID: 30955858
2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672



Back Back Return Top Page